Individual Nutritional Intervention for the Prevention of Readmission Among Geriatric Patients

October 10, 2018 updated by: Jens Rikardt Andersen

Individual Nutritional Intervention for the Prevention of Readmission Among Geriatric Patients - a Randomized Clinical Study

The purpose of this study is to investigate whether a four-week individual nutritional intervention can reduce the readmission/hospitalization rate among geriatric patients who are discharged to their private home or respite care. Secondarily, whether an individual nutritional intervention can improve nutritional status, functional status, quality of life, muscle strength and reduce mortality in geriatric patients after discharge Two sub-points are investigated using feasibility studies - if photography documentation of meals can be used in practice to assess the energy and protein intake of geriatric patients and whether photography documentation of the refrigerator content at first home visits in the intervention group can predict whether there is an increased risk of readmission.

Study Overview

Status

Completed

Conditions

Detailed Description

Method/Design:

The trial is conducted as a randomized clinical trial, with recruitment of 40 medical geriatric patients (definition: ≥65 years of age with at least two diagnoses, e.g. hypertension, cardiovascular diseases, diabetes, chronic obstructive pulmonary disease, rheumatic diseases or apoplexy). At discharge the test subjects are randomized to receive either individual dietary counseling or standard treatment with follow-up 30 and 60 days after discharge. All data are collected prior to randomization. The intervention consists of three individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the subjects (the first at the hospital by discharge, then in week 1 and week 3 at the subject's home/the respite care after discharge) and, if necessary, telephone follow-up in weeks 2 and 4 after discharge. The intervention group, if possible, are asked to take photos of all they eat and drink for two days before individual dietary counselling and send the photos electronically to the responsible investigators before the meeting.

Recruitment:

Only admitted patients are included in the trial. Attending physician finds the patients through the Health Platform at Sydsjællands University Hospital. The care staff or the attending physician asks whether the patient is willing to talk with the responsible investigators. The responsible investigators then make personal contact with the geriatric patients while they are hospitalized. Patients will be informed orally and in writing about the trial of the responsible investigators. Patients also receive pamphlets about test subjects rights in a health science research project published by the National Science Ethics Committee with the purpose of giving patients an informed basis to make a decision.

Patients are informed that they can take a family member or friend to the next conversation. Patients receive at least 24 hours of deliberation time, after which they are contacted by the responsible investigators. Patients who wish to participate in the trial are asked to sign a consent statement. This statement is also signed by the responsible investigator who has given the patient oral information about the trial. The subjects are offered a copy of the consent statement. To ensure uninterrupted conversation, conversation will take place in a room without other people or alternatively in the patient's room and a partition will be put of if the patient is not in a room by them self.

Patients who meet the inclusion criteria, wishes to participate in the trial and have signed the consent statement will be contacted again on the date of discharge or the day before, where the trial starts. Test subject may at any time, orally, in writing or by other clear indication, withdraw their consent for participation and withdraw from the trial.

Sample size:

Based on the primary output "readmission/hospitalization of geriatric patients within a month", the sample size is estimated to be at least 20 subjects in the intervention and control groups, respectively. A total of at least 40 subjects.

Statistical analysis:

Hypothesis testing will take place using nonparametric statistical tests, as the data can not be assumed to be normal distribution (Mann-Whitney U and Wilcoxon). Fisher's exact test [M1] is used for analysis of categorical data. Correlations are analyzed using Spermann analysis

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Køge, Denmark, 4600
        • Sjaellands Universitetshospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • recruited at Medical Department at Sjælland University Hospital, Køge (sections M1, M2, M6, L1) and discharged to one of following municipalities: Greve, Køge, Roskilde, Solrød and Stevns
  • geriatric patients according to the definition
  • competent adult and Danish speaking who are able to give written consent
  • oral nutrition possible (no tube feeding or intravenous nutrition)
  • discharged planned for home or respite care or similar (e.g. family).

Exclusion Criteria:

  • diagnosed dementia or under investigation for dementia
  • nursing home resident or discharged to nursing homes
  • terminal patients
  • patients who desire weight loss
  • scheduled readmission.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: individual dietary counselling
three individual dietary counsellings. The first at the hospital by discharge, then in week 1 and week 3 at the subject's home/the respite care after discharge and, if necessary, telephone follow-up in weeks 2 and 4 after discharge
individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
No Intervention: Control
standard counselling provided by the hospital at discharge. The standard counselling may include nutritional prescription and nutritional plan, but no follow-up to the nutrition plan after the discharge.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
readmission-or hospitalization rate (%)
Time Frame: 30 days after discharge
readmission for the same diagnosis as at discharge. Hospitalization for a new diagnosis
30 days after discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
readmission-/hospitalization rate (%)
Time Frame: 60 days after discharge
readmission for the same diagnosis as at discharge. Hospitalization for a new diagnosis
60 days after discharge
number of days between readmission or hospitalization and discharge (days)
Time Frame: 30 and 60 days after discharge
date minus date
30 and 60 days after discharge
nutritional status (%)
Time Frame: 30 and 60 days after discharge
The proportion of subject who has covered at least 75% of estimated energy and protein needs
30 and 60 days after discharge
functional status (score, points)
Time Frame: 30 and 60 days after discharge
Functional recovery score: P-ADL, I-ADL and mobility
30 and 60 days after discharge
Quality of Life (score, points)
Time Frame: 30 and 60 days after discharge
EQ-5D-5L
30 and 60 days after discharge
muscle strenght (dyn)
Time Frame: 30 and 60 days after discharge
Hand-grip strenght
30 and 60 days after discharge

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
mortality (%)
Time Frame: 30 and 60 days after discharge
% died from any cause
30 and 60 days after discharge
side effects in connection with the intervention (number)
Time Frame: 30 and 60 days after discharge
any side-effects reported
30 and 60 days after discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jens Rikardt Andersen, ass. prof., University of Copenhagen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 8, 2018

Primary Completion (Actual)

May 1, 2018

Study Completion (Actual)

June 15, 2018

Study Registration Dates

First Submitted

April 9, 2018

First Submitted That Met QC Criteria

April 25, 2018

First Posted (Actual)

May 8, 2018

Study Record Updates

Last Update Posted (Actual)

October 11, 2018

Last Update Submitted That Met QC Criteria

October 10, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • H-17039329

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

anonymised individual participant data for primary and secondarily outcomes measurement will be made available

IPD Sharing Time Frame

data will be available within one year of study completion

IPD Sharing Access Criteria

Author or co-author from the University of Copenhagen

IPD Sharing Supporting Information Type

  • Study Protocol

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Readmission

Clinical Trials on individual dietary counselling

3
Subscribe